Illumina, Inc.

XTRA:ILU Stock Report

Market Cap: €21.5b

Illumina Valuation

Is ILU undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ILU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ILU (€136.08) is trading below our estimate of fair value (€147.84)

Significantly Below Fair Value: ILU is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ILU?

Key metric: As ILU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ILU. This is calculated by dividing ILU's market cap by their current revenue.
What is ILU's PS Ratio?
PS Ratio5.2x
SalesUS$4.39b
Market CapUS$22.67b

Price to Sales Ratio vs Peers

How does ILU's PS Ratio compare to its peers?

The above table shows the PS ratio for ILU vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
SRT3 Sartorius
4.5x9.3%€13.7b
1SXP SCHOTT Pharma KGaA
4.3x10.7%€4.1b
GXI Gerresheimer
1.3x10.3%€2.6b
EVT Evotec
2.1x12.1%€1.6b
ILU Illumina
5.2x4.8%€22.7b

Price-To-Sales vs Peers: ILU is expensive based on its Price-To-Sales Ratio (5.2x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does ILU's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
ILU 5.2xIndustry Avg. 4.4xNo. of Companies8PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ILU is expensive based on its Price-To-Sales Ratio (5.2x) compared to the European Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is ILU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ILU PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.2x
Fair PS Ratio4.4x

Price-To-Sales vs Fair Ratio: ILU is expensive based on its Price-To-Sales Ratio (5.2x) compared to the estimated Fair Price-To-Sales Ratio (4.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ILU forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€136.08
€156.17
+14.8%
16.1%€241.00€113.86n/a25
Nov ’25€136.54
€144.38
+5.7%
19.0%€231.69€96.54n/a24
Oct ’25€118.00
€134.26
+13.8%
20.2%€226.72€94.47n/a23
Sep ’25€118.28
€133.35
+12.7%
19.3%€217.51€94.37n/a23
Aug ’25€113.28
€135.97
+20.0%
22.3%€223.46€92.34n/a22
Jul ’25€99.69
€137.50
+37.9%
22.3%€225.91€93.35n/a22
Jun ’25€95.21
€142.91
+50.1%
23.8%€232.51€91.90n/a22
May ’25€117.16
€147.50
+25.9%
23.0%€237.52€93.88n/a23
Apr ’25€128.32
€147.62
+15.0%
23.4%€238.03€78.42n/a22
Mar ’25€130.74
€147.40
+12.7%
23.4%€238.08€78.44n/a22
Feb ’25€133.00
€142.46
+7.1%
29.8%€238.21€73.86n/a24
Jan ’25€128.70
€135.04
+4.9%
32.4%€233.70€45.29n/a24
Dec ’24€98.33
€141.37
+43.8%
38.1%€239.69€46.10n/a21
Nov ’24€101.08
€185.69
+83.7%
24.0%€300.22€94.41€136.5421
Oct ’24€125.18
€200.90
+60.5%
25.4%€300.80€94.59€118.0021
Sep ’24€157.20
€205.60
+30.8%
19.2%€293.10€138.26€118.2821
Aug ’24€172.40
€214.38
+24.3%
17.7%€292.12€133.59€113.2820
Jul ’24€172.58
€224.40
+30.0%
17.5%€307.84€137.43€99.6919
Jun ’24€184.88
€224.65
+21.5%
17.7%€308.92€137.91€95.2119
May ’24€188.62
€223.10
+18.3%
17.5%€304.44€136.73€117.1619
Apr ’24€209.70
€225.47
+7.5%
16.2%€279.36€139.68€128.3220
Mar ’24€184.38
€226.95
+23.1%
16.8%€282.09€139.65€130.7420
Feb ’24€193.68
€229.12
+18.3%
16.2%€275.97€147.18€133.0020
Jan ’24€187.02
€241.69
+29.2%
19.4%€330.19€150.94€128.7018
Dec ’23€210.45
€249.18
+18.4%
19.3%€338.03€154.53€98.3316
Nov ’23€224.45
€263.17
+17.3%
18.9%€344.15€177.14€101.0816

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Teva Pharmaceutical Industries

US$18.8b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$15.65

7D

-3.7%

1Y

76.2%

Collegium Pharmaceutical

US$1.0b

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.60

7D

5.7%

1Y

27.6%

Pharming Group

€491.5m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.70

7D

-0.7%

1Y

-34.1%